ASCO GI 2021 | Bemarituzumab + mFOLFOX6 in first-line advanced gastric/gastroesophageal junction adenocarcinoma

Daniel Catenacci, MD, University of Chicago, Chicago, IL, discusses the results of the FIGHT study (NCT03694522), a double-blind placebo-controlled Phase II study of bemarituzumab, an FGFR2b targeting antibody in combination with modified FOLFOX6 (mFOLFOX6) in the first-line treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma. In this Phase II study, the addition of bemarituzumab to mFOLFOX6 led to clinically meaningful and statistically significant improvements in progression-free survival, overall survival, and overall response rate. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).